1.1Acetaminophen as the active ingredient
Acetaminophen provides analgesia after oral absorption. Microcrystalline cellulose supports tablet compression, and crospovidone draws water into the tablet to promote breakup.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Acetaminophen provides analgesia after oral absorption. Microcrystalline cellulose supports tablet compression, and crospovidone draws water into the tablet to promote breakup.
Ibuprofen inhibits cyclooxygenase and reduces prostaglandin production. A blend of ibuprofen granules, microcrystalline cellulose, and croscarmellose sodium forms a tablet that disintegrates after contact with gastrointestinal fluid.
A gravimetric filler meters the powder into individual foil pouches and checks the fill mass. The sealed pouch limits moisture uptake and opens to dispense the measured powder.
A jet mill reduces the size of the crystals, increasing the surface area available for dissolution. Croscarmellose sodium promotes tablet breakup and exposes the particles to gastrointestinal fluid.
Polysorbate 80 wets the crystal surfaces, and xanthan gum increases the viscosity of the aqueous vehicle to slow settling. Shaking redistributes the particles before an oral syringe measures the dose.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A materials testing laboratory uses a dried dispersion of otenaproxesul in a pharmaceutical polymer as a low-crystallinity reference. The laboratory blends separate aliquots of the dispersion with measured amounts of crystalline otenaproxesul to create a calibration series. Powder X-ray diffraction measures the intensity of characteristic crystalline peaks across the series and relates peak intensity to crystalline content.
Copovidone serves as the pharmaceutical excipient and forms a matrix around amorphous otenaproxesul. A spray dryer atomizes a single-phase solution of the drug and copovidone, and the drying gas removes the solvent as the droplets form solid particles. Powder X-ray diffraction with crystalline calibration measures whether at least 95 percent by weight of the drug is amorphous.
Three spray-dried batches contain 10, 20, and 30 percent otenaproxesul by dry dispersion weight, with copovidone making up the balance. The spray dryer uses the same nozzle and total feed solids concentration for all three batches. A calibrated powder X-ray diffraction assay checks each batch against a target of at least 95 percent amorphous drug by weight.
A capsule filling line receives a dried dispersion of amorphous otenaproxesul and a pharmaceutical polymer. A dry blender combines the dispersion with microcrystalline cellulose and colloidal silicon dioxide before a dosing station meters the blend into hard capsule shells. An inline checkweigher verifies capsule mass, and a calibrated powder X-ray diffraction assay checks the amorphous drug fraction in sampled capsule contents.
A cold-form foil blister line packages tablets containing amorphous otenaproxesul dispersed in a pharmaceutical polymer. The line places one tablet into each formed cavity and heat-seals a foil lidding web over the cavities. A storage study measures tablet moisture and crystalline drug content at scheduled intervals to track solid form stability in the sealed package.
A Raman probe measures the dried otenaproxesul dispersion through an optical window in the powder discharge line. A regression model trained on reference blends in the same excipient matrix estimates the crystalline fraction by weight of the drug. The controller diverts powder to a separate collection vessel when the estimated crystalline fraction exceeds 5 percent.
Microcrystalline cellulose provides a compressible matrix for an oral tablet containing amorphous otenaproxesul. Croscarmellose sodium takes up water and swells, breaking the tablet into smaller particles.
Colloidal silicon dioxide reduces cohesion in a powder blend containing an amorphous otenaproxesul dispersion. A dosing machine meters the blend into hard capsules.
A spray dryer atomizes a common solvent solution of otenaproxesul and copovidone into a heated gas stream. Rapid solvent removal forms a solid dispersion, and quantitative powder X-ray diffraction verifies that crystalline drug accounts for no more than 5 wt % of the drug content.
A twin-screw extruder mixes otenaproxesul with softened vinylpyrrolidone–vinyl acetate copolymer, and a chilled belt cools the extrudate before milling. Powder X-ray diffraction calibrated with crystalline drug reference mixtures verifies that at least 95 wt % of the drug is amorphous.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The present invention also provides a pharmaceutical pill, tablet, capsule, powder, or slurry (or other pharmaceutically effective and acceptable form) comprising a pharmaceutical excipient as disclosed.A · US 2016/0184438 A1 · ¶ 80
In yet other embodiments, the present disclosure provides substantially amorphous pharmaceutical formulations comprising 5-10% anhydrous carbamazepine (CBZ) and 10%-90% polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.B · US 2021/0129406 A1 · ¶ 15
An empty cell means only that no passage was reproduced there.
An excipient is a natural or synthetic substance formulated alongside the active ingredient of a medication, included for the purpose of bulking-up formulations that contain potent active ingredients (also referred to as “bulking agents,” “fillers,” or “diluents”), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption or solubility.A · US 2016/0184438 A1 · ¶ 6
Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance concerned such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation over the expected shelf life.A · US 2016/0184438 A1 · ¶ 6
Therefore, there exists a need for improved methods that extend the processing window and employ less harsh conditions in the preparation of various drugs as solid dispersions.B · US 2021/0129406 A1 · ¶ 5
Therefore, by using drug hydrates/solvates in extrusion, the process conditions can be significantly eased, and the processing window can be greatly extended to be able to prepare various drugs as solid dispersions.B · US 2021/0129406 A1 · ¶ 6
patent.fyi, US 2026/0355142 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355142/, SHA-256 c42bfc77db1b5ec913e737f3d0762820a7041e6e282d47ee1b4b06bdd81329ba